BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 31017019)

  • 1. Patent landscape of molecular and cellular targeted therapies for recessive dystrophic epidermolysis bullosa.
    Dourado Alcorte M; Sogayar MC; Demasi MA
    Expert Opin Ther Pat; 2019 May; 29(5):327-337. PubMed ID: 31017019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.
    Cutlar L; Greiser U; Wang W
    Exp Dermatol; 2014 Jan; 23(1):1-6. PubMed ID: 24107073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa.
    Atanasova VS; Jiang Q; Prisco M; Gruber C; Piñón Hofbauer J; Chen M; Has C; Bruckner-Tuderman L; McGrath JA; Uitto J; South AP
    J Invest Dermatol; 2017 Sep; 137(9):1842-1849. PubMed ID: 28549954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovative therapeutic strategies for recessive dystrophic epidermolysis bullosa.
    Larcher F; Del Río M
    Actas Dermosifiliogr; 2015 Jun; 106(5):376-82. PubMed ID: 25796272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model.
    Turczynski S; Titeux M; Tonasso L; Décha A; Ishida-Yamamoto A; Hovnanian A
    J Invest Dermatol; 2016 Dec; 136(12):2387-2395. PubMed ID: 27498345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratinocyte-/fibroblast-targeted rescue of Col7a1-disrupted mice and generation of an exact dystrophic epidermolysis bullosa model using a human COL7A1 mutation.
    Ito K; Sawamura D; Goto M; Nakamura H; Nishie W; Sakai K; Natsuga K; Shinkuma S; Shibaki A; Uitto J; Denton CP; Nakajima O; Akiyama M; Shimizu H
    Am J Pathol; 2009 Dec; 175(6):2508-17. PubMed ID: 19893033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.
    Perdoni C; Osborn MJ; Tolar J
    Transl Res; 2016 Feb; 168():50-58. PubMed ID: 26073463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seven novel COL7A1 mutations identified in patients with recessive dystrophic epidermolysis bullosa from Mexico.
    Saeidian AH; Youssefian L; Moreno Trevino MG; Fortuna G; Vahidnezhad H; Atanasova VS; Uitto J; Salas-Alanis JC; South AP
    Clin Exp Dermatol; 2018 Jul; 43(5):579-584. PubMed ID: 29473190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratinocyte cell lines derived from severe generalized recessive epidermolysis bullosa patients carrying a highly recurrent COL7A1 homozygous mutation: models to assess cell and gene therapies in vitro and in vivo.
    Chamorro C; Almarza D; Duarte B; Llames SG; Murillas R; García M; Cigudosa JC; Espinosa-Hevia L; Escámez MJ; Mencía A; Meana A; García-Escudero R; Moro R; Conti CJ; Del Río M; Larcher F
    Exp Dermatol; 2013 Sep; 22(9):601-3. PubMed ID: 23947675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five Novel
    Yan Y; Meng Z; Hao S; Wang F; Jin X; Sun D; Gao H; Ma X
    Ann Clin Lab Sci; 2018 Jan; 48(1):100-105. PubMed ID: 29531004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.
    Wang X; Alshehri F; Manzanares D; Li Y; He Z; Qiu B; Zeng M; A S; Lara-Sáez I; Wang W
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations.
    van den Akker PC; van Essen AJ; Kraak MM; Meijer R; Nijenhuis M; Meijer G; Hofstra RM; Pas HH; Scheffer H; Jonkman MF
    J Dermatol Sci; 2009 Oct; 56(1):9-18. PubMed ID: 19665875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
    Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
    JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
    Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
    J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
    Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
    J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune reactivity to type VII collagen: implications for gene therapy of recessive dystrophic epidermolysis bullosa.
    Pendaries V; Gasc G; Titeux M; Leroux C; Vitezica ZG; Mejía JE; Décha A; Loiseau P; Bodemer C; Prost-Squarcioni C; Hovnanian A
    Gene Ther; 2010 Jul; 17(7):930-7. PubMed ID: 20376098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa.
    Murauer EM; Gache Y; Gratz IK; Klausegger A; Muss W; Gruber C; Meneguzzi G; Hintner H; Bauer JW
    J Invest Dermatol; 2011 Jan; 131(1):74-83. PubMed ID: 20720561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.
    Twaroski K; Eide C; Riddle MJ; Xia L; Lees CJ; Chen W; Mathews W; Keene DR; McGrath JA; Tolar J
    Br J Dermatol; 2019 Dec; 181(6):1247-1253. PubMed ID: 30924923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa.
    Wenzel D; Bayerl J; Nyström A; Bruckner-Tuderman L; Meixner A; Penninger JM
    Sci Transl Med; 2014 Nov; 6(264):264ra165. PubMed ID: 25429058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.